Differential metabolic profiles mediated SLC1A2 confer resistance in glioblastoma therapies : stratification goals and implementation
Glioblastoma (GBM) is the most lethal malignant brain tumor, where its epigenetic, metabolic and molecular heterogeneity contribute largely to therapeutic resistance and relapse. Better elucidation of key oncogenic nodes as well as metabolic regulators driving the proliferation and drug resistance o...
Saved in:
Main Author: | Koh, Lynnette Wei Hsien |
---|---|
Other Authors: | Tan Nguan Soon |
Format: | Thesis-Doctor of Philosophy |
Language: | English |
Published: |
Nanyang Technological University
2020
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/138683 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Designer therapies for glioblastoma multiforme
by: Sith Sathornsumetee, et al.
Published: (2018) -
SLC5 and SLC2 transporters in epithelia-cellular role and molecular mechanisms
by: Mobeen Raja, et al.
Published: (2018) -
Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma
by: Justyna Magdalena Przystal, et al.
Published: (2019) -
Adaptive mechanoproperties mediated by the formin FMN1 characterize glioblastoma fitness for invasion
by: Monzo, Pascale, et al.
Published: (2022) -
Association of SLC1A2 and SLC17A7 polymorphisms with major depressive disorder in a Thai population
by: Benjamard Thaweethee, et al.
Published: (2020)